33 Results
NIH Launches Study of Extra COVID-19 Vaccine Dose in People with Autoimmune Disease
August 27, 2021
The National Institutes of Health has begun a clinical trial to assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune disease who did not respond to an original COVID-19 vaccine regimen. The trial also will investigate whether pausing immunosuppressive therapy for autoimmune disease improves the antibody response to an extra dose of a COVID-19 vaccine in this population.
NIH Scientists Describe “Multi-Kingdom Dialogue” Between Internal, External Microbiota
June 23, 2021
National Institutes of Health scientists and their collaborators have identified an internal communication network in mammals that may regulate tissue repair and inflammation, providing new insights on how diseases such as obesity and inflammatory skin disorders develop.
Gene Therapy Restores Immune Function in Children with Rare Immunodeficiency
May 11, 2021
An investigational gene therapy can safely restore the immune systems of infants and children who have a rare, life-threatening inherited immunodeficiency disorder, according to research supported in part by the National Institutes of Health.
NIH Statement on World Asthma Day 2021
May 5, 2021
On World Asthma Day, the National Institutes of Health reaffirms its commitment to research to improve the lives of people with asthma. More than 25 million people in the United States have asthma, including 5.1 million children, according to the Centers for Disease Control and Prevention. This chronic lung disease can reduce quality of life, contributes to considerable emotional and financial stress, and is a major contributing factor to missed time from school and work.
COVID-19 Vaccine Responses to be Studied in People with Immune Deficits
April 23, 2021
A study assessing how people with immune system deficiencies or dysregulations respond to COVID-19 vaccination has begun enrolling participants at the National Institutes of Health Clinical Center in Bethesda, Maryland. The single-site study is led by researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and aims to enroll 500 people, 400 with primary or secondary immune system disorders and 100 without such conditions.
NIH Establishes New Childhood Asthma Clinical Research Network
April 23, 2021
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded $10 million in first-year funding to establish a clinical research network called Childhood Asthma in Urban Settings (CAUSE). This nationwide network will conduct observational studies and clinical trials to improve understanding of asthma and develop treatment and prevention approaches tailored to children of low-income families living in urban communities. NIAID intends to provide approximately $70 million over seven years to support the CAUSE network.
NIH Clinical Trial Evaluating Moderna COVID-19 Variant Vaccine Begins
March 31, 2021
An investigational vaccine designed to protect against the B.1.351 SARS-CoV-2 variant has been administered as part of a new Phase 1 clinical trial evaluating the vaccine candidate’s safety and immunogenicity in adult volunteers. The vaccine, known as mRNA-1273.351, was developed by the biotechnology company ModernaTX, Inc., based in Cambridge, Massachusetts. The trial is led and funded by NIAID. The trial will enroll approximately 210 healthy adult volunteers at four clinical research sites in the United States that are part of the NIAID-funded Infectious Diseases Clinical Research Consortium (IDCRC).
NIH Study of Early Predictors, Mechanisms of Food Allergy and Eczema has Begun
March 19, 2021
A study to identify prenatal and early childhood markers of high risk for food allergy and atopic dermatitis, or eczema, as well as biological pathways that lead to these conditions, has begun. The observational study of children from birth to age 3 years will examine the origins of allergic disease by integrating interdisciplinary analyses of data from more than 260 biological and environmental samples and survey responses from each of 2,500 families.
